Natera Announces National Commercial Coverage for its Fetal RhD NIPT
Portfolio Pulse from
Natera, Inc. has announced that its Fetal RhD noninvasive prenatal test (NIPT) will receive national commercial coverage from a major US payor starting January 2025. This coverage applies when a pregnancy is at risk for alloimmunization or when paternal antigen typing is unavailable.
February 03, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's Fetal RhD NIPT will receive national commercial coverage from a major US payor starting January 2025, potentially increasing the test's adoption and revenue.
The announcement of national commercial coverage for Natera's Fetal RhD NIPT by a major US payor is likely to increase the test's adoption, as it will be more accessible to patients. This could lead to higher revenues for Natera, positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90